Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Neutral rating

Analyst Ratings For Allogene Therapeutics Inc (NASDAQ:ALLO)

Story continues below

Today, JPMorgan Chase & Co. initiated coverage on Allogene Therapeutics Inc (NASDAQ:ALLO) with a Neutral.

There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Allogene Therapeutics Inc (NASDAQ:ALLO) is Buy with a consensus target price of N/A per share, a potential N/A.

Some recent analyst ratings include

  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Neutral rating
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy rating
  • 11/5/2018-Allogene Therapeutics Inc (NASDAQ:ALLO) has coverage initiated with a Buy rating


    Recent Trading Activity for Allogene Therapeutics Inc (NASDAQ:ALLO)
    Shares of Allogene Therapeutics Inc closed the previous trading session at 27,69 +0,74 2,75 % with 27.32 shares trading hands.

    An ad to help with our costs